Boehringer Ingelheim launches phase 1 trial for triple-action obesity drug
July 1, 2024 / Boehringer Ingelheim / Obesity / Triple-action Obesity Drug / Clinical Trials / Obesity Epidemic
Boehringer Ingelheim, with Gubra, launches a Phase 1 trial for BI 3034701, a triple-action peptide targeting obesity, assessing safety, tolerability, and pharmacokinetics in 124 participants.
New study reveals ketogenic diet’s role in combating obesity
July 1, 2024 / Ketogenic Diet / Obesity / Metabolic Health
A ketogenic diet (KD) promotes obesity protection by altering gut microbiota and increasing bile acids, specifically TUDCA and TDCA, which lower fasting glucose and body weight, per a study in Nature Metabolism.
A trio of trials on hormone receptor agonists for MASLD
July 1, 2024 /MASLD Treatment / Hormone Receptor / Liver / GLP1R Agonists / GIPR Agonists
Three Phase II trials show promise for hormone receptor agonists in treating metabolic dysfunction-associated steatotic liver disease (MASLD), highlighting advancements in therapies that also address type 2 diabetes and obesity.
25% of adults with SMA in German study had metabolic syndrome
July 1, 2024 / Spinal Muscular Atrophy / Metabolic Syndrome / Quality of Life
A German study found that 25% of adults with spinal muscular atrophy (SMA) have metabolic syndrome, impacting their quality of life and increasing fatigue.
Activation of the osteoblastic HIF-1α pathway partially alleviates the symptoms of STZ-induced type 1 diabetes mellitus via RegIIIγ
July 1, 2024 / Diabetes / Metabolism / Osteoblst Glucose Metabolism
Activating the HIF-1α pathway in osteoblasts alleviates symptoms of type 1 diabetes in mice, enhancing glucose metabolism and protecting pancreatic β cells, indicating a potential therapeutic target.
Preventing Diabetic Nerve and Brain Issues with Herbal Remedies
July 1, 2024 / Diabetic Neuropathy Prevention / Diabetes / Herbal Remedies
A NUST study shows that Nigella sativa and Cassia angustifolia can mitigate diabetic neuropathy and cognitive deficits in hyperglycemic mice, suggesting potential benefits for diabetes management.
Compound from olives shows promise for treating obesity and diabetes
June 29, 2024 / Elenolic Acid / Health Benefits / Obesity / Weight Loss / Type 2 Diabetes
Elenolic acid from olives may reduce blood sugar and promote weight loss, showing potential for managing obesity and type 2 diabetes, as demonstrated in a recent mouse study.
Natural compound found in olives can lower blood sugar levels and promote weight loss
June 29, 2024 /Elenolic Acid Benefits / Weight Loss / Natural Diabetes Treatment
Elenolic acid, a compound in olives, lowers blood sugar and promotes weight loss in mice, showing potential as a safe, cost-effective treatment for obesity and type 2 diabetes.
Anti-Obesity Medications: Their Current and Future Role in Bariatric Surgery
June 28, 2024 / Anti-Obesity / Bariatric Surgery / Obesity Comorbidities
Anti-obesity medications are increasingly integral to bariatric surgery, addressing comorbidities like cardiovascular disease, diabetes, and cancers associated with metabolic syndrome and obesity.
Plant-based meat alternatives show no significant heart health benefits in recent study
June 28, 2024 / Plant-based meat / Cardiovascular Health / Cardiometabolic Biomarkers
An eight-week study found no significant cardiovascular benefits from plant-based meat alternatives compared to an omnivorous diet, despite changes in dietary fiber, potassium, sodium, and trans-fat levels among participants.
Daily Intake Of Milk Protein Concentrate May Improve Anthropometric And Metabolic Markers In Obese Women On Hypocaloric Diet
June 27, 2024 / Protien / Metabolic Markers / Hypocaloric Diet
Daily intake of milk protein concentrate may improve anthropometric and metabolic markers in obese women on hypocaloric diet suggests a study published in BMC Nutrition.
Advancing diabetes research and serving an at-risk community
June 27, 2024 / Metabolic Syndrome / Health Initiatives / Diabetes
The Center for Disparities in Diabetes, Obesity, and Metabolism focuses on Latino health, leveraging a biobank to facilitate research and improve diabetes care, highlighting the significant health disparities and the impact of socio-economic factors.
Severe digestive symptoms in glycogen storage disease linked to gut microbiota
June 27, 2024 / Glycogen storage disease gut microbiota / GSD / Bowel Diease / Gut Microbiome
A study links severe digestive symptoms in glycogen storage disease (GSD) to gut microbiota imbalances, highlighting macrophage and CCL4L2-VSIR pathway roles in inflammatory bowel disease (IBD) development in GSD-Ib patients.
Rapeseed diacylglycerol oil may combat obesity by enhancing lipid metabolism
June 26, 2024 / Rapeseed Diacylglycerol Oil / Obesity Prevention / Functional Fat Benefits
Rapeseed diacylglycerol oil (RDG) enhances lipid metabolism and may reduce obesity, as shown in a mouse study, suggesting potential as a healthier alternative to traditional vegetable oils.
Association between individualized metabolic surgery scores and weight-loss outcomes in patients treated with semaglutide
June 26, 2024 / Weight-Loss / Type 2 Diabetes / Metabolic Surgery
A Mayo Clinic study found that semaglutide’s weight-loss efficacy in patients with type 2 diabetes varies by individualized metabolic surgery (IMS) score, with those having severe scores experiencing less significant weight loss.
Cortisol Might Play Role in Tough-to-Treat Diabetes
June 26, 2024 / Cortisol / Diabetes / Hypercortisolism
A study reveals that elevated cortisol levels contribute to tough-to-treat type 2 diabetes, affecting 24% of patients. Addressing hypercortisolism, potentially through adrenal surgery, may improve diabetes management.
Novel genetic predisposition to being overweight or obese identified
June 25, 2024 / SMM1 / Obesity / Metabolic Changes
A study identifies a genetic predisposition to obesity linked to SMIM1 loss-of-function, highlighting its impact on metabolism and potential for personalized therapies.
Low-salt diets can lead to systemic insulin resistance, raising significant health concerns: study
June 25, 2024 / Low-salt Diet Risks / Insulin Resistance. / Sympathetic Nervous System Activation / Metabolism
Low-salt diets can cause systemic insulin resistance by activating the sympathetic nervous system, reducing muscle blood flow, and increasing stress hormones, raising concerns about their universal recommendation.
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
June 25, 2024 /Phase 3 Trial / Cardiovascular Outcomes Trial / RNAi / Familial chylomicronemia syndrome
Arrowhead Pharmaceuticals is advancing the RNAi-based drug plozasiran into a Phase 3 cardiovascular outcomes trial, CAPITAN, following successful Phase 3 and Phase 2 studies showing significant triglyceride reduction in patients with FCS, severe hypertriglyceridemia, and mixed hyperlipidemia.
Scientists discover link between birthweight and risk of health complications from childhood obesity
June 24, 2024 / Birthweight / Obesity / Cardiometabolic Diesease
Researchers at the University of Copenhagen found that children with low birth weight are at higher risk of health complications from childhood obesity, emphasizing the need for targeted prevention and treatment strategies.
AI
Bariatric Surgery
Cardio-Kidney-Metabolic Syndrome
Cardiometabolic
Cardiovascular
Clinical Trials
Diabetes
GLP-1
Insulin
MASH
Metabolic Disease
Metabolic Dysfunction
Metabolic Syndrome
Obesity
Type 2 Diabetes
Weight Gain
Weight Loss